SBIO (SBIO) Stock Price & Analysis
SBIO (SBIO) fell 0.87% to USD 63.77 as of July 26, 2026 at 20:01 UTC, according to Nexqual real-time market data.
SBIO last closed at USD 64.33; the session ranged USD 63.34–64.77 on volume of 14,837 shares. Market capitalization is —, with a 52-week range of USD 32.35–69.34 (PCX). Source: Nexqual, July 26, 2026 at 20:01 UTC.
Key Statistics (as of July 26, 2026 at 20:01 UTC)
| Price | USD 63.77 |
|---|---|
| Change | ▼ 0.87% (down) |
| Previous Close | USD 64.33 |
| Open | USD 64.62 |
| Day Range | USD 63.34 – 64.77 |
| 52-Week Range | USD 32.35 – 69.34 |
| Volume | 14,837 shares |
| Market Cap | — |
| Exchange | PCX |
Technical Analysis (SBIO)
Nexqual's technical model rates SBIO "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 26, 2026 at 20:01 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.33 (neutral) |
| vs SMA50 | Above (USD 58.33) |
| MACD | 1.6 (positive) |
Financial Health Score (SBIO)
Nexqual rates SBIO's overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 20:01 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Mixed — No data |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBC | Virtus Biotech Clinical Trials | USD 49.67 | ▼ 1.87% |
| BBP | Virtus Biotech ETF | USD 96.39 | ▼ 0.58% |
| ROM | ProShares Ultra Technology | USD 130.92 | ▼ 4.96% |
| FBT | First Trust Amex Biotech Index | USD 247.39 | ▲ 0.9% |
| KBA | KraneShares Bosera MSCI China A | USD 33.61 | ▼ 1.29% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 20:01 UTC. This page is informational and not investment advice.